Allergan posts 10.6% sales growth, updates Levadex plans
This article was originally published in Scrip
Executive Summary
Allergan posted strong revenue growth in the second quarter of 2013 that is consistent with its double-digit annual growth goals and the company said it will respond to the US FDA's second rejection of the inhaled migraine drug Levadex (dihydroergotamine) by the end of the year.